pharmaphorum
JUNE 23, 2022
Eisai’s digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese project aimed at improving the management of dementia. The smartphone app – which uses a cognition-checking algorithm developed by Australian digital health company Cogstate – will be deployed in Bunkyo City, Tokyo in a dementia monitoring programme.
MedCity News
JUNE 23, 2022
Mental health is bucking the overall trend in telehealth utilization. A new report found that telehealth accounted for 87% of mental health appointments booked last month. That percentage is continuing to climb, despite virtual care visits declining across all other specialties.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
JUNE 23, 2022
The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.
MedCity News
JUNE 23, 2022
Medallion — a provider management platform that automates licensing, continuing education tracking, credentialing and compliance — has completed three funding rounds in one year. On Thursday, it closed a $35 million Series C round, which will be used to help the startup attract more hospital and health system customers.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
JUNE 23, 2022
The European Commission (EC) has approved Novartis’ Tabrecta (capmatinib) as a monotherapy to treat advanced non-small cell lung cancer (NSCLC) in adults. The treatment is intended for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping and for those who need systemic therapy after previous treatment with immunotherapy and/or platinum-based chemotherapy.
MedCity News
JUNE 23, 2022
Confidentiality agreements typically prevent the public from obtaining a window into the cases against pharmacy behemoths but a public court filing makes this one different.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
JUNE 23, 2022
Two private equity firms have reached an $890 million deal to buy Radius Health, a company whose main asset is the commercialized osteoporosis drug Tymlos. In other M&A news, cancer biotech F-star Therapeutics is being acquired in a $161 million deal.
pharmaphorum
JUNE 23, 2022
Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). The Swiss pharma group is paying $75 million upfronting cash and equity to get the ball rolling on the collaboration, with another $1.4 billion in potential milestones if the project advances through development and onto the market.
MedCity News
JUNE 23, 2022
The Pitch Perfect contest at MedCity INVEST PharmaTech, the free virtual conference scheduled for July 26, will spotlight five startups seeking to improve clinical trials.
pharmaphorum
JUNE 23, 2022
Around the world, women are making important contributions to life sciences. In this series, we chart the career progression of notable women across the industry to find out what drew them to study science and how we can encourage more women to consider a role in STEM. In this edition, Giulia Guerrini, the lead pharmacist for digital pharmacy medino, discusses her journey from classics student in Italy to start-up superintendent and why it’s important to champion women in leadership positions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
JUNE 23, 2022
Leaders in healthcare draw attention to the myriad ways cloud computing technology is transforming healthcare.
Integrity Solutions
JUNE 23, 2022
It’s the “r” word no one wants to utter, but many experts worry that a potential recession could be looming somewhere out there on the horizon. While the data doesn’t suggest a major downturn is imminent, and things like strength in the labor market and financial system could fend it off entirely, there are numerous warning signs that have economists cautioning that “the economy faces headwinds.” And for many salespeople it will be the first recession theyR
Pharmaceutical Technology
JUNE 23, 2022
In the last year, well-known contract manufacturing organisations (CMOs) such as Agilent Technologies (Santa Clara, California) and Abzena (Cambridge, UK) have expanded their continuous manufacturing capabilities. US Congress is also making substantial investments to improve the continuous manufacturing of pharmaceuticals. As more drugs are approved with continuous manufacturing, this production method is becoming increasingly mainstream.
PharmaTimes
JUNE 23, 2022
Global surveillance systems show that recorded cases do not include any deaths
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
JUNE 23, 2022
The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The vaccine is intended for active immunisation to prevent invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in people aged six weeks and above.
PharmaTimes
JUNE 23, 2022
The company has renewed its pledge to eliminate neglected tropical diseases and malaria over five years
Pharmaceutical Technology
JUNE 23, 2022
As recent changes to the price setting of drugs have improved the market access risk environment in France, GlobalData looks at their impact on the pricing of orphan drugs. Changes to price negotiations positive for orphan drugs. The changes in question were introduced via the new contractual agreement signed by the French Pharmaceutical Companies Association (LEEM) and the Ministry of Health’s (MoH’s) Economic Committee for Health Products (CEPS) in March 2021.
PharmaVoice
JUNE 23, 2022
Even execs get the blues — and when they’re ready for a fresh start, Leslie Loveless, CEO of Slone Partners, says these dos and don’ts could make or break their next job move.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Rep-Lite
JUNE 23, 2022
Can you imagine building a medical sales team from scratch? Is it even possible to organize a new group of competent sales representatives to go to the field and compete with other medical rep sales companies? The answer is yes! Rep Lite is here to provide you with the best people to fill your sales rep jobs and comprise a success-driven team you have never had.
Pharmaceutical Technology
JUNE 23, 2022
The metaverse will make digital media experiences more immersive, inclusive, and accessible than today. However, it will raise social concerns ranging from data privacy to other forms of online harm. Listed below are the key regulatory trends impacting the metaverse theme, as identified by GlobalData. Net neutrality. Net neutrality refers to the concept that a telecom network should be a neutral gateway to the Internet rather than a gatekeeper with the power to decide what content is available o
Clarivate
JUNE 23, 2022
In our new oncology report, we analyzed paragraph IV certification and post-grant patent litigation trends impacting generic drug strategies on antineoplastic and immunomodulating therapies. Our analysis suggests notably that the jurisdictions chosen for infringement and validity challenge cases over the past 10 years are changing, and past favorites may no longer be the most strategic. .
Pharmaceutical Technology
JUNE 23, 2022
Researchers at the University of New Hampshire (UNH) have found that a repurposed drug, CCG-50014, could hinder the activity of a key enzyme of the SARS-CoV-2 virus, which causes Covid-19. Utilising a currently available drug compound in a new way is called drug repurposing. The main protease enzyme Mpro, a key enzyme related to Covid-19, was the key target of the team in the study.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Clarivate
JUNE 23, 2022
As part of our Drugs to Watch series, our team of oncology experts pored over thousands of abstracts for presentations at this year’s just-concluded American Society of Clinical Oncology (ASCO) Annual Meeting. One trend stood out clearly: the prominence of innovative treatments, including antibody drug conjugates (ADCs) and bispecific antibodies. ADCs and bispecifics aren’t new.
Pharmaceutical Technology
JUNE 23, 2022
Gaming and social media companies are at the vanguard of metaverse development, but enterprises will lead the charge in the next three years. This shift will be driven by the future of work and digital transformation initiatives ongoing across sectors ranging from retail to healthcare and financial services. Big Tech is championing the metaverse, with Microsoft and Meta promoting it as the ideal environment to support hybrid working.
pharmaphorum
JUNE 23, 2022
US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant. The suit – filed in a Massachusetts district court – claims that Paxlovid (nirmatrelvir and ritonavir) infringes its 11,358,953 patent which covers “compounds and pharmaceutically acceptable salts which inhibit coronavirus replication activity, and methods of treating a coronavirus infection” and wa
Pharmaceutical Technology
JUNE 23, 2022
The global healthcare and pharmaceutical industry is frequently faced with having to find new ways of innovating and carrying out its work in order to overcome tragic circumstances that will typically come with a huge human cost. During the peak of the Covid-19 pandemic this challenge reached new heights, as pharmaceutical firms around the world mobilised the full might of their resources to try and identify, develop, and trial a wide range of vaccines and therapeutics to alleviate the lethal th
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
pharmaphorum
JUNE 23, 2022
Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body. The so-called “tumour-agnostic” indication for BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib) covers patients aged six and over with tumours that have progressed after earlier treatment and have no alternative therapies available.
Pharmaceutical Technology
JUNE 23, 2022
The proportion of pharmaceutical companies hiring for robotics related positions rose in May 2022 compared with the equivalent month last year, with 20.8% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 19.7% of companies who were hiring for robotics related jobs a year ago but a decrease compared to the figure of 21.8% in April 2022.
Copyright Clearance Center
JUNE 23, 2022
The post Building Networked Innovation appeared first on Copyright Clearance Center.
PharmExec
JUNE 23, 2022
In episode 111, Kevin Ali, CEO of Organon, talks about how’s he’s lead the launch of a new niche company for women’s health, and what he hopes it can achieve.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
122 
Let's personalize your content